small molecule

NESINA

ALOGLIPTIN BENZOATE

Loss of exclusivityJune 2029latest FDA-listed patent expiry

CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand name	NESINA
Active ingredient	ALOGLIPTIN BENZOATE
Strength	EQ 6.25MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	January 2013
Marketing status	RX

Listed patents

Patent	Expires	Type
8697125	June 2029	product
7807689	June 2028	substance, product

Regulatory exclusivity

Code	Expires
M-300	July 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from TAKEDA PHARMACEUTICALS USA INC